Geode Capital Management
CYCN

Geode Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Geode Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Sell
45,850
-38,700
-46% -$126K ﹤0.01% 3993
2026
Q1 		$130K Buy
84,550
+41,248
+95% +$58.7K ﹤0.01% 4065
2025
Q4 		$55K Buy
43,302
+6,144
+17% +$11K ﹤0.01% 4218
2025
Q3 		$85.5K Buy
37,158
+4,423
+14% +$12K ﹤0.01% 4169
2025
Q2 		$95.3K Buy
32,735
+1,132
+4% +$3.38K ﹤0.01% 4071
2025
Q1 		$78.1K Sell
31,603
-217
-0.7% -$646 ﹤0.01% 4099
2024
Q4 		$102K Sell
31,820
-2,088
-6% -$5.81K ﹤0.01% 4091
2024
Q3 		$87.5K Sell
33,908
-70
-0.2% -$206 ﹤0.01% 4144
2024
Q2 		$77.5K Buy
33,978
+1,896
+6% +$5.39K ﹤0.01% 4196
2024
Q1 		$103K Buy
32,082
+823
+3% +$2.63K ﹤0.01% 4153
2023
Q4 		$105K Buy
31,259
+510
+2% +$1.47K ﹤0.01% 4177
2023
Q3 		$105K Buy
30,749
+1,027
+3% +$3.7K ﹤0.01% 4235
2023
Q2 		$122K Buy
29,722
+110
+0.4% +$570 ﹤0.01% 4254
2023
Q1 		$257K Buy
29,612
+275
+0.9% +$3.47K ﹤0.01% 3922
2022
Q4 		$385K Buy
29,337
+146
+0.5% +$1.73K ﹤0.01% 3795
2022
Q3 		$502K Buy
29,191
+506
+2% +$8.7K ﹤0.01% 3725
2022
Q2 		$314K Sell
28,685
-484
-2% -$6.93K ﹤0.01% 4007
2022
Q1 		$647K Buy
29,169
+877
+3% +$21.1K ﹤0.01% 3816
2021
Q4 		$973K Buy
28,292
+3,759
+15% +$178K ﹤0.01% 3738
2021
Q3 		$1.51M Buy
24,533
+5,292
+28% +$346K ﹤0.01% 3485
2021
Q2 		$1.5M Sell
19,241
-5,107
-21% -$320K ﹤0.01% 3397
2021
Q1 		$1.36M Buy
24,348
+2,655
+12% +$199K ﹤0.01% 3430
2020
Q4 		$1.33M Buy
21,693
+4,044
+23% +$276K ﹤0.01% 3273
2020
Q3 		$2.15M Buy
17,649
+1,841
+12% +$211K ﹤0.01% 2843
2020
Q2 		$1.87M Sell
15,808
-342
-2% -$28.6K ﹤0.01% 2882
2020
Q1 		$855K Buy
16,150
+1,131
+8% +$80.7K ﹤0.01% 3077
2019
Q4 		$817K Buy
15,019
+2,725
+22% +$254K ﹤0.01% 3346
2019
Q3 		$2.98M Buy
12,294
+222
+2% +$48K ﹤0.01% 2695
2019
Q2 		$2.76M Buy
+12,072
New +$3.42M ﹤0.01% 2744

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management's CYCN Position: Q2 2026 in Review

Geode Capital Management reduced its Cyclerion Therapeutics (CYCN) stake by 46% in Q2 2026, selling an estimated $126K and leaving 45,850 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #3993.

Geode Capital Management first reported a position in CYCN in Q2 2019 and has held it in 29 quarters since. The position peaked at $2.98M in Q3 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Geode Capital Management held 45,850 shares of Cyclerion Therapeutics worth $155K as of Q2 2026.
  • Geode Capital Management sold 38,700 Cyclerion Therapeutics shares in Q2 2026, an estimated $126K.
  • Cyclerion Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3993 holding.
  • Geode Capital Management first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Geode Capital Management's Cyclerion Therapeutics position peaked at $2.98M in Q3 2019.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.